[A new approach to treating secondary pulmonary hypertension].

Objective: to study the clinical and hemodynamic effects and safety of the ACE inhibitor dirotone and AT1-receptor antagonist losartan in secondary pulmonary hypertension (PH) in patients with chronic obstructive bronchitis (COB).

Subjects And Methods: The time course of changes in hemodynamic parameters and diurnal BP profile in 48 patients with COB concurrent with Functional Class (FC) III-IV secondary PH, receiving 4-week therapy including dirotone and losartan.

Results: The inclusion of dirotone or losartan into the combined therapy of patients with secondary pulmonary hypertension resulted in alleviated PH, caused positive changes in the right cardiac cavities, and normalized diurnal BP variables.

[Hemodynamics, blood gas composition and viscosity in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale].

Hemodynamics, external respiratory function (ERF), blood gas composition and viscosity were studied in 120 patients with chronic obstructive bronchitis at different developmental stage of cor pulmonale. In pulmonary hypertension, there were moderate ERF disorders that became more marked in the compensatory and particularly decompensatory cor pulmonale. As bronchial patency deteriorated, the index of right ventricular performance increased from 0.

[Blockers of angiotensin receptors: a novel approach to the treatment of secondary pulmonary hypertension].

Aim: To evaluate efficacy of losartan, a blocker of angiotensin receptors, in combined treatment of secondary pulmonary hypertension (SPH) in patients with chronic obstructive bronchitis (COB).

Material And Methods: Losartan effects on hemodynamics, blood gases and clinical course of the disease were studied in 29 patients with COB and SPH (mean age 52 +/- 1.7 years).

[Efficiency of perstarium in the treatment of patients with chronic obstructive bronchitis and pulmonary hypertension].

Thirty-two patients with chronic obstructive bronchitis (COB) aged 38 to 52 years (mean 40.5 +/- 3.8 years) who had clinical and functional parameters of NYHA functional class (FC) IV (WHO, 1998) pulmonary hypertension (PH).

[Clinical and hemodynamical efficacy of prestarium and its role in the treatment of chronic pulmonary heart].

Aim: To assess clinical efficiency and safety of ACE inhibitor prestarium (Servier, France) with specification of its effects on central and pulmonary hemodynamics, hepatic blood flow, indications in patients with chronic pulmonary heart (CPH).

Material And Methods: 42 patients with chronic obstructive bronchitis (COB) complicated by CPH entered the trial. The patients were divided into two groups.